☆
4.2
Article
2.23 Covalent Inhibition of Btk with Clinical Development Compound AVL-292 Disrupts Signaling That Maintains the Microenvironment Necessary for Chronic Lymphocytic Leukemia Growth
Clinical Lymphoma Myeloma & Leukemia (2011)
Rate this paper
The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started